David Cochran, Ph.D.
Director, Pharma and Biotech Investments
David Cochran, Ph.D., serves as Director of Pharma and Biotech Investments at 215 Capital, where he oversees the firm’s portfolio in the life sciences sector. He brings nearly two decades of experience spanning pharmaceutical R&D, biologics development, and manufacturing innovation.
Prior to joining 215 Capital, Dr. Cochran held senior research and technical leadership roles at Johnson & Johnson Consumer Healthcare, where he directed cross-functional teams in the development and scale-up of solid dose and liquid products, spearheaded clinical manufacturing operations, and led R&D due diligence efforts in mergers and acquisitions. His work included advancing novel dosage forms, overseeing GMP pilot facilities, and driving digital innovation initiatives across the enterprise. Earlier in his career, Dr. Cochran conducted research in therapeutics, biomaterials, and nanomedicine, with multiple peer-reviewed publications and patents in the areas of antioxidant polymers and drug delivery.
Dr. Cochran holds a Ph.D. in Chemical Engineering from the University of Kentucky, an M.S. in Chemical Engineering from Drexel University, and a B.S. in Chemical Engineering from Drexel University. He also earned an MBA from Texas A&M University.
